Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 6 of 6 results for vutrisiran

  1. Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (TA1115)

    Evidence-based recommendations on vutrisiran (Amvuttra) for wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.

    Technology appraisal guidance
    Published
    10 December 2025
    View recommendations

    Sections for TA1115

  2. Vutrisiran for treating hereditary transthyretin-related amyloidosis (TA868)

    Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults.

    Technology appraisal guidance
    Published
    15 February 2023
    View recommendations

    Sections for TA868

  3. Eplontersen for treating hereditary transthyretin-related amyloidosis (TA1020)

    Evidence-based recommendations on eplontersen (Wainzua) for treating hereditary transthyretin-related amyloidosis in adults.

    Technology appraisal guidance
    Published
    27 November 2024
    View recommendations

    Sections for TA1020

  4. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)

    Evidence-based recommendations on tafamidis (Vyndaqel) for treating transthyretin amyloidosis with cardiomyopathy in adults.

    Technology appraisal guidance
    Published
    19 June 2024
    View recommendations

    Sections for TA984

  5. Taking a proportionate approach to technology appraisals

    Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.

  6. NICE welcomes life sciences review recommendations

    NICE’s priority is to get the best care to patients fast while ensuring value for the taxpayer.

    News
    Last updated
    22 January 2024